Source comparison
Wolverine Stack MK-677 Extended Recovery: Comparison
MK-677 Solo Ghrelin receptor agonist; sustained GH/IGF-1 elevation 20–25mg/day oral 18–24 hours anabolic signaling per dose Increased appetite, mild water retention, possible insulin resistance at prolonged high dose Solid baseline for systemic recovery; limit
This comparison does not assign a generated winner or score.
- MK-677 Solo
- Ghrelin receptor agonist; sustained GH/IGF-1 elevation
- 20–25mg/day oral
- 18–24 hours anabolic signaling per dose
- Increased appetite, mild water retention, possible insulin resistance at prolonged high dose
- Solid baseline for systemic recovery; limited tissue-specific repair
- MK-677 + BPC-157
- GH elevation + VEGF upregulation, anti-inflammatory
- MK: 20–25mg/day; BPC: 250–500mcg twice daily subQ
- 24+ hours; combines systemic anabolism with localised tissue repair
- Low; BPC-157 well-tolerated with minimal reported AEs
- Synergistic for soft tissue injuries; BPC targets inflammation pathways MK-677 doesn't reach
- MK-677 + TB-500
- GH elevation + actin regulation, fibroblast migration
- MK: 20–25mg/day; TB: 2–5mg twice weekly subQ
- 5–7 days per TB-500 dose (long half-life); MK sustains anabolic environment
- Minimal; TB-500 has favorable safety profile in animal models
- Best for connective tissue repair (tendons, ligaments); TB-500's 10-day half-life means less frequent dosing
- MK-677 + CJC-1295 (no DAC)
- Dual GH secretagogue (ghrelin + GHRH pathways)
- MK: 20–25mg/day; CJC: 100–200mcg 2–3x weekly subQ
- Marginal extension; risk of receptor saturation
- Elevated; potential for supraphysiological IGF-1, glucose dysregulation
- Redundant unless MK-677 alone fails to elevate IGF-1 adequately; most users hit diminishing returns
- Wolverine Stack (MK-677 + BPC-157 + TB-500)
- Triple-pathway: GH/IGF-1 + inflammation control + structural repair
- MK: 20–25mg/day; BPC: 250mcg 2x/day; TB: 2.5mg 2x/week
- 7+ days; sustained anabolic + active tissue remodeling + vascular support
- Moderate; primarily MK-677-driven (appetite, water); BPC/TB add minimal burden
- Comprehensive for multi-tissue injury or post-surgical recovery; addresses systemic and localised pathways
- MK-677 + MOTS-c
- GH elevation + mitochondrial biogenesis
- MK: 20–25mg/day; MOTS-c: 5–10mg 2–3x weekly subQ
- Extends metabolic recovery; improves ATP production efficiency
- Low to moderate; MOTS-c may cause transient fatigue during adaptation
- Useful when recovery plateau is metabolic (poor endurance, chronic fatigue) rather than tissue damage